• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在 COVID-19 大流行期间,英格兰糖尿病患者常规护理提供减少与非 COVID-19 相关死亡率之间的关联:一项基于人群的平行队列研究。

Associations between reductions in routine care delivery and non-COVID-19-related mortality in people with diabetes in England during the COVID-19 pandemic: a population-based parallel cohort study.

机构信息

NHS England and Improvement, Skipton House, London, UK; Department of Diabetes and Endocrinology, St Mary's Hospital, Imperial College Healthcare NHS Trust, London, UK; Division of Metabolism, Digestion, and Reproduction, Imperial College London, London, UK.

NHS England and Improvement, Skipton House, London, UK.

出版信息

Lancet Diabetes Endocrinol. 2022 Aug;10(8):561-570. doi: 10.1016/S2213-8587(22)00131-0. Epub 2022 May 27.

DOI:10.1016/S2213-8587(22)00131-0
PMID:35636440
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9141683/
Abstract

BACKGROUND

The Office for Health Improvement and Disparities, part of the UK Government Department of Health and Social Care, highlighted an emerging signal of increased non-COVID-19-related deaths in England between July and October, 2021, with a potentially disproportionate higher increase in people with diabetes. We aimed to substantiate and quantify this apparent excess mortality, and to investigate the association between diabetes routine care delivery and non-COVID-19-related-mortality in people with diabetes before and after the onset of the pandemic.

METHODS

In this population-based parallel cohort study, we used the National Diabetes Audit (NDA) to identify people with diabetes in England. The primary outcome was non-COVID-19-related deaths between July 3, 2021, and Oct 15, 2021, in participants in the 2021 COVID-19 cohort (registered in the NDA in the periods Jan 1, 2019, to March 31, 2020, and Jan 1, 2020, to March 31, 2021) compared with deaths between June 29, 2019, and Oct 11, 2019 (the equivalent 15-week period in 2019) in the 2019 pre-COVID-19 comparator cohort (people registered in the NDA in the periods Jan 1, 2017, to March 31, 2018, and Jan 1, 2018 to March 31, 2019). In each cohort, multivariable logistic regression examined whether completion of eight diabetes care processes in each of the two years before the index mortality year was associated with non-COVID-19-related death, adjusting for diabetes type, age, sex, ethnicity, and socioeconomic deprivation.

FINDINGS

There were 3 218 570 people in the 2021 cohort and 2 973 645 people in the 2019 comparator cohort. In the 2021 cohort, there were 30 118 non-COVID-19-related deaths in people with diabetes, compared with 27 132 in the comparator cohort, representing an 11% increase (95% CI 9-13). The unadjusted incidence rate ratio (IRR) for mortality in the 2021 cohort compared to the 2019 cohort was 1·026 (1·009-1·043; p=0·003), which was unchanged after adjustment for age, sex, ethnicity, socioeconomic deprivation, and diabetes type (IRR 1·023 (1·006-1·040); p=0·007). In the 2021 cohort, 853 660 (26·5%) people received all eight care processes in 2020-21 compared with 1 547 240 (48·1%) people in 2019-20; a 44·8% (95% CI 44·7-45·0) relative reduction. In the pre-COVID-19 comparator cohort, 1 370 315 (46·1%) people with diabetes received all eight care processes in 2018-19 compared with 1 437 740 (48·3%) in 2017-18; a 4·7% (95% CI 4·5-4·9) relative decrease. Non-COVID-19-related mortality in the 2021 cohort was highest in people who did not receive all eight care processes in either of the two previous years (OR 2·67 [95% CI 2·56-2·77]; p<0·001) compared with those who received all eight care processes in both previous years. Mortality was also significantly higher in those who received all eight care processes in 2019-20 but not in 2020-21 (OR 1·66 [95% CI 1·59-1·73]; p<0·001) or not in 2019-20 but in 2020-21 (OR 1·27 [1·20-1·35]; p<0·001). This pattern of association was similar in the 2019 pre-COVID-19 cohort.

INTERPRETATION

Our results show an increased risk of mortality in those who did not receive all eight care processes in one or both of the previous two years. Our results provide evidence that the increased rate of non-COVID-19-related mortality in people with diabetes in England observed between July 3, and Oct 15 of 2021 is associated with a reduction in completion of routine diabetes care processes following the pandemic onset in 2020.

FUNDING

None.

摘要

背景

英国卫生部下属的卫生和社会保健部下属的改善健康和减少不平等办公室强调,2021 年 7 月至 10 月期间,英格兰与 COVID-19 无关的死亡人数出现了一个新的信号,患有糖尿病的人死亡人数增加的幅度可能不成比例。我们旨在证实并量化这种明显的超额死亡率,并调查 2021 年 COVID-19 大流行之前和之后,糖尿病常规护理的提供与糖尿病患者与 COVID-19 无关的死亡率之间的关联。

方法

在这项基于人群的平行队列研究中,我们使用国家糖尿病审计(NDA)来确定英格兰的糖尿病患者。主要结局是在 2021 年 COVID-19 队列(在 NDA 中注册的时间为 2019 年 1 月 1 日至 3 月 31 日和 2020 年 1 月 1 日至 3 月 31 日)中,2021 年 7 月 3 日至 10 月 15 日期间,与 COVID-19 无关的死亡人数,与 2019 年 6 月 29 日至 10 月 11 日(2019 年同期的 15 周)在 2019 年 COVID-19 之前的比较队列(在 NDA 中注册的时间为 2017 年 1 月 1 日至 3 月 31 日和 2018 年 1 月 1 日至 3 月 31 日)相比。在每个队列中,多变量逻辑回归检查了在指数死亡率年度之前的两年中,完成八项糖尿病护理过程的情况是否与非 COVID-19 相关的死亡有关,调整了糖尿病类型、年龄、性别、种族和社会经济贫困情况。

结果

2021 年队列中有 3218570 人,2019 年比较队列中有 2973645 人。在 2021 年队列中,有 30118 例与 COVID-19 无关的糖尿病相关死亡,而在比较队列中为 27132 例,增加了 11%(95%CI 9-13)。与 2019 年队列相比,2021 年队列的死亡率未调整发病率比(IRR)为 1.026(1.009-1.043;p=0.003),在调整了年龄、性别、种族、社会经济贫困和糖尿病类型后,IRR 为 1.023(1.006-1.040)(p=0.007)。在 2021 年队列中,2020-21 年有 853660 人(26.5%)接受了所有八项护理过程,而 2019-20 年有 1547240 人(48.1%);相对减少了 44.8%(95%CI 44.7-45.0)。在 2019 年 COVID-19 之前的比较队列中,2018-19 年有 1370315 人(46.1%)接受了所有八项护理过程,而 2017-18 年有 1437740 人(48.3%);相对减少了 4.7%(95%CI 4.5-4.9)。在 2021 年队列中,在过去两年中都没有接受所有八项护理过程的人,与在过去两年中都接受了所有八项护理过程的人相比,与 COVID-19 无关的死亡率最高(OR 2.67 [95%CI 2.56-2.77];p<0.001)。与在 2019-20 年接受了所有八项护理过程但在 2020-21 年没有接受的人相比,在 2020-21 年接受了所有八项护理过程的人死亡率也显著升高(OR 1.66 [95%CI 1.59-1.73];p<0.001),或在 2019-20 年没有接受但在 2020-21 年接受的人(OR 1.27 [1.20-1.35];p<0.001)。这种关联模式在 2019 年 COVID-19 之前的队列中也相似。

结论

我们的结果表明,在过去一年或两年中没有接受所有八项护理过程的人,其死亡风险增加。我们的结果提供了证据,表明在 2021 年 7 月 3 日至 10 月 15 日期间,英格兰与 COVID-19 无关的死亡人数增加,与 2020 年大流行后常规糖尿病护理过程的完成减少有关。

资金

无。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcfc/9141683/a7527931992a/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcfc/9141683/f35898118aef/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcfc/9141683/35b82b1c04be/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcfc/9141683/a7527931992a/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcfc/9141683/f35898118aef/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcfc/9141683/35b82b1c04be/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcfc/9141683/a7527931992a/gr3_lrg.jpg

相似文献

1
Associations between reductions in routine care delivery and non-COVID-19-related mortality in people with diabetes in England during the COVID-19 pandemic: a population-based parallel cohort study.在 COVID-19 大流行期间,英格兰糖尿病患者常规护理提供减少与非 COVID-19 相关死亡率之间的关联:一项基于人群的平行队列研究。
Lancet Diabetes Endocrinol. 2022 Aug;10(8):561-570. doi: 10.1016/S2213-8587(22)00131-0. Epub 2022 May 27.
2
Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study.英格兰 1 型和 2 型糖尿病患者 COVID-19 相关死亡率的风险因素:一项基于人群的队列研究。
Lancet Diabetes Endocrinol. 2020 Oct;8(10):823-833. doi: 10.1016/S2213-8587(20)30271-0. Epub 2020 Aug 13.
3
Child mortality in England after national lockdowns for COVID-19: An analysis of childhood deaths, 2019-2023.英国因新冠疫情实施全国封锁后的儿童死亡率:2019 - 2023年儿童死亡情况分析
PLoS Med. 2025 Jan 23;22(1):e1004417. doi: 10.1371/journal.pmed.1004417. eCollection 2025 Jan.
4
Deaths involving COVID-19 by self-reported disability status during the first two waves of the COVID-19 pandemic in England: a retrospective, population-based cohort study.英格兰 COVID-19 大流行前两波期间自我报告残疾状况导致的 COVID-19 死亡:一项回顾性、基于人群的队列研究。
Lancet Public Health. 2021 Nov;6(11):e817-e825. doi: 10.1016/S2468-2667(21)00206-1. Epub 2021 Oct 7.
5
Incidence of diabetes after SARS-CoV-2 infection in England and the implications of COVID-19 vaccination: a retrospective cohort study of 16 million people.英格兰地区 2019 冠状病毒病(COVID-19)大流行期间感染 SARS-CoV-2 后发生糖尿病的发病率:一项涉及 1600 万人的回顾性队列研究。
Lancet Diabetes Endocrinol. 2024 Aug;12(8):558-568. doi: 10.1016/S2213-8587(24)00159-1.
6
Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study.1 型和 2 型糖尿病与英格兰 COVID-19 相关死亡率的关联:一项全人群研究。
Lancet Diabetes Endocrinol. 2020 Oct;8(10):813-822. doi: 10.1016/S2213-8587(20)30272-2. Epub 2020 Aug 13.
7
Impact of the COVID-19 pandemic on health-care use among patients with cancer in England, UK: a comprehensive phase-by-phase time-series analysis across attendance types for 38 cancers.英国英格兰地区2019冠状病毒病疫情对癌症患者医疗服务利用情况的影响:对38种癌症不同就诊类型的全面逐阶段时间序列分析
Lancet Digit Health. 2024 Oct;6(10):e691-e704. doi: 10.1016/S2589-7500(24)00152-3.
8
Changes in COVID-19-related mortality across key demographic and clinical subgroups in England from 2020 to 2022: a retrospective cohort study using the OpenSAFELY platform.2020 年至 2022 年期间英格兰与关键人口统计学和临床亚组相关的 COVID-19 死亡率变化:使用 OpenSAFELY 平台的回顾性队列研究。
Lancet Public Health. 2023 May;8(5):e364-e377. doi: 10.1016/S2468-2667(23)00079-8.
9
Excess years of life lost to COVID-19 and other causes of death by sex, neighbourhood deprivation, and region in England and Wales during 2020: A registry-based study.2020 年英格兰和威尔士因 COVID-19 和其他死因导致的超额寿命损失及其与性别、社区贫困程度和地区的关系:一项基于登记的研究。
PLoS Med. 2022 Feb 15;19(2):e1003904. doi: 10.1371/journal.pmed.1003904. eCollection 2022 Feb.
10
Estimating excess 1-year mortality associated with the COVID-19 pandemic according to underlying conditions and age: a population-based cohort study.根据潜在疾病和年龄估计与 COVID-19 大流行相关的超额 1 年死亡率:一项基于人群的队列研究。
Lancet. 2020 May 30;395(10238):1715-1725. doi: 10.1016/S0140-6736(20)30854-0. Epub 2020 May 12.

引用本文的文献

1
Optimising cardiac surgery outcomes in people with diabetes: the OCTOPuS pilot feasibility study.优化糖尿病患者心脏手术的预后:OCTOPuS试点可行性研究
Health Technol Assess. 2025 Aug;29(39):1-31. doi: 10.3310/POYW3311.
2
COVID-19 pandemic and risk factor measurement in individuals with cardio-renal-metabolic diseases: A retrospective study in the United Kingdom.2019冠状病毒病大流行与心肾代谢疾病患者的风险因素测量:英国的一项回顾性研究
PLoS One. 2025 Apr 24;20(4):e0319438. doi: 10.1371/journal.pone.0319438. eCollection 2025.
3
Effect of the COVID-19 pandemic on diabetic retinopathy and referral levels in the English National Health Service Diabetic Eye Screening Programme.
2019年冠状病毒病大流行对英国国家医疗服务体系糖尿病眼病筛查项目中糖尿病视网膜病变及转诊水平的影响。
Diabet Med. 2025 May;42(5):e15518. doi: 10.1111/dme.15518. Epub 2025 Feb 3.
4
Comparison of mortality in people with type 2 diabetes between different ethnic groups: Systematic review and meta-analysis of longitudinal studies.不同种族2型糖尿病患者死亡率的比较:纵向研究的系统评价和荟萃分析
PLoS One. 2025 Jan 17;20(1):e0314318. doi: 10.1371/journal.pone.0314318. eCollection 2025.
5
Introduction of electronic death notification in Norway-Impact on diabetes mortality registration.挪威电子死亡通知的引入——对糖尿病死亡率登记的影响
PLoS One. 2024 Dec 2;19(12):e0311106. doi: 10.1371/journal.pone.0311106. eCollection 2024.
6
Impact of the COVID-19 Pandemic on Lifestyle Behavior and Clinical Care Pathway Management in Type 2 Diabetes: A Retrospective Cross-Sectional Study.COVID-19 大流行对 2 型糖尿病患者生活方式行为和临床护理路径管理的影响:一项回顾性横断面研究。
Medicina (Kaunas). 2024 Oct 4;60(10):1624. doi: 10.3390/medicina60101624.
7
The impact of hospital saturation on non-COVID-19 hospital mortality during the pandemic in France: a national population-based cohort study.医院饱和对法国大流行期间非 COVID-19 医院死亡率的影响:一项全国基于人群的队列研究。
BMC Public Health. 2024 Jul 5;24(1):1798. doi: 10.1186/s12889-024-19282-3.
8
Podcast on the IWGDF 2023 Guidelines on the Prevention of Foot Ulcers in Persons with Diabetes.关于国际糖尿病足工作组(IWGDF)2023年糖尿病患者足部溃疡预防指南的播客。
Diabetes Ther. 2024 Apr 26. doi: 10.1007/s13300-024-01578-7.
9
The impact of telehealth education on self-management in patients with coexisting type 2 diabetes mellitus and hypertension: a 26-week randomized controlled trial.远程医疗教育对同时患有 2 型糖尿病和高血压的患者自我管理的影响:一项 26 周的随机对照试验。
J Endocrinol Invest. 2024 Sep;47(9):2361-2369. doi: 10.1007/s40618-024-02310-9. Epub 2024 Feb 14.
10
The impact of a statewide insulin copay cap policy for insured patients with diabetes in Utah.犹他州针对参保糖尿病患者的全州胰岛素自付费用上限政策的影响。
J Manag Care Spec Pharm. 2024 Feb 3;30(2):112-117. doi: 10.18553/jmcp.2024.30.2.112.